Evidence map›Paper›PMID 33040613›Full record

ArticleCirculation2021

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.

Pardeep S Jhund, Scott D Solomon, Kieran F Docherty, Hiddo J L Heerspink, Inder S Anand, Michael Böhm, Vijay Chopra, Rudolf A de Boer, Akshay S Desai, Junbo Ge and 17 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03036124. Cited by 121 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03036124 phase3completed

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Ran2017Enrolled4,744Registered outcomes6Posted comparisons6ConditionsChronic Heart Failure With Reduced Ejection Fraction (HFrEF)Armsdapagliflozin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Effect of dapagliflozin on anaemia in DAPA-HF.European journal of heart failure · 2021
    Trial

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Pardeep S JhundBHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (P.S.J., K.F.D., J.J.V.M.).
Scott D SolomonDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (S.D.S., A.S.D.).
Kieran F DochertyBHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (P.S.J., K.F.D., J.J.V.M.).
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology (H.J.L.H.), University Medical Center Groningen, University of Groningen, The Netherlands.
Inder S AnandDepartment of Cardiology, University of Minnesota, Minneapolis (I.S.A.).
Michael BöhmDepartment of Medicine, Saarland University Hospital, Homburg-Saar, Germany (M.B.).
Vijay ChopraDepartment of Cardiology, Max Super Speciality Hospital, Saket, New Delhi, India (V.C.).
Rudolf A de BoerDepartment of Cardiology (R.A.d.B.), University Medical Center Groningen, University of Groningen, The Netherlands.
Akshay S DesaiDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (S.D.S., A.S.D.).
Junbo GeDepartment of Cardiology, Shanghai Institute of Cardiovascular Disease and Zhongshan Hospital Fudan University, China (J.G.).
Masafumi KitakazeCardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan (M.K.).
Bela MerkleyHeart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.).
Eileen O'MearaDepartment of Cardiology, Montreal Heart Institute, Canada (E.O.).
Morten ShouDepartment of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (M. Shou).
Sergey TereshchenkoDepartment of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russia (S.T.).
Subodh VermaDivision of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Canada (S.V.).
Pham Nguyen VinhDepartment of Internal Medicine, Tan Tao University, Tan Duc, Vietnam (P.N.V.).
Silvio E InzucchiSection of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.).
Lars KøberDepartment of Cardiology, Rigshospitalet, Copenhagen University Hospital, Denmark (L.K.).
Mikhail N KosiborodSaint Luke's Mid America Heart Institute, University of Missouri, Kansas City (M.N.K.).
Felipe A MartinezUniversidad Nacional de Córdoba, Córdoba, Argentina (F.A.M.).
Piotr PonikowskiCenter for Heart Diseases, University Hospital, Wroclaw Medical University, Poland (P.P.).
Marc S SabatineTIMI Study Group, Brigham and Women's Hospital, Boston, MA (M.S.S.).
Olof BengtssonLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., A.M.L., M. Sjöstrand).
Anna Maria LangkildeLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., A.M.L., M. Sjöstrand).
Mikaela SjöstrandLate Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (O.B., A.M.L., M. Sjöstrand).
John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (P.S.J., K.F.D., J.J.V.M.).

Funding

Yale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI Kevan C Herold, GERALD I SHULMAN · 1993 to 2026
$44.0M
British Heart Foundation RE/18/6/34217NIDDK NIH HHS P30 DK045735
6 · The paper itself

Abstract

backgroundMany patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated with worse outcomes. We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to baseline kidney function, in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure). We also examined the effect of dapagliflozin on kidney function after randomization.

methodsPatients who have HFrEF with or without type 2 diabetes and an estimated glomerular filtration rate (eGFR) ≥30 mL·min

resultsOf 4742 patients with a baseline eGFR, 1926 (41%) had eGFR <60 mL·min

conclusionsBaseline kidney function did not modify the benefits of dapagliflozin on morbidity and mortality in HFrEF, and dapagliflozin slowed the rate of decline in eGFR, including in patients without diabetes. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.

Indexed as

AgedBenzhydryl CompoundsFemaleGlucosidesHeart FailureHumansKidneyMaleMiddle AgedRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsStroke VolumeBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsheart failurekidney function testsrenal insufficiency, chronicsodium-glucose transporter 2 inhibitors

Identifiers

PMID33040613
PMCPMC7834909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.